Black Diamond Therapeutics (BDTX) EPS (Basic) Growth (3y) (2021 - 2026)
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) EPS (Basic) Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - | 28.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.63% |
| Mar 31, 2026 | 32.20% |
| Dec 31, 2025 | 20.87% |
| Sep 30, 2025 | 33.76% |
| Jun 30, 2025 | 29.87% |
| Mar 31, 2025 | 50.31% |
| Dec 31, 2024 | 22.98% |
| Sep 30, 2024 | 31.15% |
| Jun 30, 2024 | 25.06% |
| Mar 31, 2024 | 22.67% |
| Dec 31, 2023 | 11.17% |
| Sep 30, 2023 | 1.35% |
| Jun 30, 2023 | -10.66% |
| Mar 31, 2023 | -3.88% |
| Dec 31, 2022 | 50.38% |
| Sep 30, 2022 | 46.82% |
| Jun 30, 2022 | 43.09% |
| Mar 31, 2022 | 28.09% |
| Dec 31, 2021 | 22.43% |